CD4 and neoplasm: Tregs make up 10% of all CD4+ T lymphocytes in the peripheral blood of healthy people, rising up to 30–50% in the presence of tumor lesions, inhibiting the activation of CD8+ T and CD4+ T lymphocytes and hence, playing an essential role in immunosuppression and angiogenesis [39,40].